moxifloxacin has been researched along with liraglutide in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (liraglutide) | Trials (liraglutide) | Recent Studies (post-2010) (liraglutide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,404 | 481 | 2,154 |
| Protein | Taxonomy | moxifloxacin (IC50) | liraglutide (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, DJ; Khutoryansky, N; Litwin, JS; Sprenger, CR; Zdravkovic, M | 1 |
1 trial(s) available for moxifloxacin and liraglutide
| Article | Year |
|---|---|
Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Female; Fluoroquinolones; Glucagon-Like Peptide 1; Heart Conduction System; Humans; Injections, Subcutaneous; Liraglutide; Male; Middle Aged; Models, Statistical; Moxifloxacin; Quinolines; Time Factors | 2009 |